巨子生物控股有限公司（股票代码：2367）于2026年1月6日发布截至2025年12月31日的股份变动月报。报告显示，公司法定注册股本为5,000,000,000股，每股面值USD 0.00001，合计USD 50,000；截至月末已发行普通股总数为1,070,904,000股，较上月无变化，库藏股数量亦为零。
公司当月无新增发行、购回或注销活动，已发行股份总数保持在1,070,904,000股。根据2023年8月17日采纳的2023年购股权计划，公司现有可行使购股权数量维持不变，本月未有期权行使或转换为新股。此外，2025年6月13日曾赎回5,200,000股普通股，但尚未注销，未对本月股本构成影响。
公司在公告中确认，所有股份发行及相关事宜均遵循香港联交所《上市规则》和适用法律法规规定。该公告由执行董事兼联席公司秘书严鈺博签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.